TRAP1 rescues PINK1 loss-of-function phenotypes.

Area of Science:

• Mitochondrial Biology
• Neurodegenerative Diseases
• Parkinson's Disease Pathogenesis

Background:

• PTEN-induced kinase 1 (PINK1) is a mitochondrial kinase crucial for cellular protection against oxidative stress and is implicated in early-onset Parkinson's disease (PD).
• Mitochondrial dysfunction is a hallmark of PINK1-associated PD.
• TNF receptor-associated protein 1 (TRAP1) has been suggested to mediate PINK1's protective effects and mitigate α-Synuclein toxicity, linking it to mitochondrial health in PD.

Purpose of the Study:

• To investigate the in vivo and in vitro potential of TRAP1 to rescue mitochondrial dysfunction caused by PINK1 or Parkin deficiency.
• To elucidate the functional role of TRAP1 in maintaining mitochondrial integrity within the context of PD-related genetic defects.

Main Methods:

• Utilized Drosophila melanogaster models to assess the effects of human TRAP1 overexpression on PINK1 and Parkin loss-of-function phenotypes.
• Employed RNA interference (RNAi) and small interfering RNA (siRNA) to silence complex I subunits and PINK1/Parkin in Drosophila and human neuronal SH-SY5Y cells, respectively.
• Evaluated mitochondrial fragmentation and dysfunction as readouts for TRAP1's rescue capabilities.

Main Results:

• Overexpression of TRAP1 mitigated PINK1 loss-of-function phenotypes in Drosophila, but not Parkin loss-of-function phenotypes.
• TRAP1 rescued detrimental effects of complex I subunit silencing in Drosophila.
• In human neuronal cells, TRAP1 rescued mitochondrial fragmentation and dysfunction upon PINK1 silencing, but not Parkin silencing.

Conclusions:

• TRAP1 plays a functional role in maintaining mitochondrial integrity downstream of PINK1 and complex I deficits.
• The data suggest TRAP1 acts parallel to or upstream of Parkin in the mitochondrial quality control pathway.
• TRAP1 represents a potential therapeutic target for mitochondrial dysfunction in specific forms of Parkinson's disease.